In patients with CHC, TRAF1lowHCV-specific CD8+ T cell function is restored through IL-7 plus 4-1BBL and PD-1 blockade treatment, indicating a promising immunotherapy for patients with CHC (148). Here, CD8A is linked to cryohydrocytosis.